List view / Grid view
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Eli Lilly scientists report that they have designed, qualified and enabled a high-throughput plasmid purification and quantification workstation.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.
Researchers at Children’s National Hospital in the US have developed a promising new gene therapy for limb-girdle muscular dystrophy (LGMD) 2B.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Tune in to this podcast to learn about AAV vectors for gene therapy delivery and engineering CAR T cells against solid tumours.
